期刊
INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY
卷 -, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1687-9856-2011-6
关键词
-
资金
- Novo Nordisk, Inc.
Objective: To identify factors associated with growth in children on growth hormone (GH) therapy using data from the American Norditropin Studies: Web-enabled Research (ANSWER) Program (R) registry. Methods: GH-naive children with GH deficiency, multiple pituitary hormone deficiency, idiopathic short stature, Turner syndrome, or a history of small for gestational age were eligible (N = 1,002). Using a longitudinal statistical approach, predictive factors were identified in patients with GHD for change from baseline in height standard deviation score (Delta HSDS) following 2 years of treatment. Results: Gradual increases in Delta HSDS over time were observed for all diagnostic categories. Significant predictive factors of Delta HSDS, ranked by significance were: height velocity (HV) at 4 months > baseline age > baseline HSDS > baseline body mass index (BMI) SDS > baseline insulin-like growth factor I (IGF-I) SDS; gender was not significant. HV at 4 months and baseline BMI SDS were positively correlated, whereas baseline age, HSDS, and IGF-I SDS were negatively correlated with Delta HSDS. Conclusions: These results may help guide GH therapy based on pretreatment characteristics and early growth response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据